Andreas Wicki - 12 Dec 2022 Form 4 Insider Report for Harmony Biosciences Holdings, Inc. (HRMY)

Reporting relationship: Director
Issuer ticker: HRMY
Reported as of: 12 Dec 2022
Net transaction value: -$1,739,342
SEC form: 4
Accepted by SEC: 14 Dec 2022, 20:01:45 UTC
Prior SEC filing: 07 Dec 2022
Source filing: View source filing
Reporting owner signature: /s/ Mehdi Khodadad, Attorney-in-fact

Key filing fact

Andreas Wicki filed Form 4 for Harmony Biosciences Holdings, Inc. (HRMY) on 14 Dec 2022.

Key facts

This page summarizes Andreas Wicki's Form 4 filing for Harmony Biosciences Holdings, Inc. (HRMY).
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 14 Dec 2022, 20:01.

Change

Previous filing in this sequence was filed on 07 Dec 2022.
Current net transaction value: -$1,739,342.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HRMY transaction

Common Stock

Sale

Transaction value: $1,351,521
Shares: -22,391
Change %: -1%
Price: $60.36
Shares after: 2,154,393
Date: 12 Dec 2022
Ownership: See Footnote
Footnotes: F1, F2

HRMY transaction

Common Stock

Sale

Transaction value: $380,022
Shares: -6,320
Change %: -0.29%
Price: $60.13
Shares after: 2,148,073
Date: 13 Dec 2022
Ownership: See Footnote
Footnotes: F2, F3

HRMY transaction

Common Stock

Sale

Transaction value: $7,800
Shares: -130
Change %: -0.01%
Price: $60.00
Shares after: 2,147,943
Date: 14 Dec 2022
Ownership: See Footnote
Footnotes: F2, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $61.17, inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote one (1) of this Form 4.

Footnote F2

These shares are held by HBM Healthcare Investments (Cayman) Ltd. ("HBM"), of which Mr. Wicki is a member of the board of directors. The board of directors of HBM acts by majority vote, and Mr. Wicki does not have sole voting or investment power with respect to the shares. Mr. Wicki disclaims beneficial ownership of such shares for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that the reporting person is a beneficial owner for the purposes of Section 16 of the Exchange Act, or for any other purpose.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.64, inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote three (3) of this Form 4.

Footnote F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.01, inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote four (4) of this Form 4.